The number of companies offering molecular diagnosis is large and growing steadily, following the demands of social pressure. In theory, many companies offer appropriate, albeit globally designed, molecular diagnosis. In some diseases, such as RP, the methodologies available allow only the analysis of the most prevalent genes or the detection of previously reported mutations. In contrast, OrigoGEN uses a high-throughput strategy that allows rapid and cost-effective analysis of all the known RP genes, thus offering a specific and client-centered diagnosis for each family.

This is OrigoGEN’s priority and commitment:
An individualized, rigorous and accessible genetic diagnosis.